Can a new antibody tame lupus flares?

NCT ID NCT07760155

Not yet recruiting Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called ESG206 can safely reduce disease activity in adults with systemic lupus erythematosus (SLE). Participants will receive either ESG206 or a placebo, and researchers will measure how many achieve a meaningful improvement in lupus symptoms by week 25. The study aims to see if targeting a protein called BAFF-R can help control the immune system's attack on the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESG206, an experimental monoclonal antibody that targets BAFF-R to help control lupus disease activity
What this could lead to: If successful, ESG206 could offer a new treatment option to help control lupus symptoms and reduce disease flares.
What could go wrong: This is an early-stage trial with a small number of participants, so results may not hold up in larger studies. The drug may also cause side effects or fail to show a clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Affiliated Hospital of Hebei Engineering University

Handan, Hebei, China
Affiliated Hospital of North Sichuan Medical College

Nanchong, Sichuan, China
Changde First People's Hospital

Changde, Hunan, China
Huzhou Third People's Hospital

Huzhou, Zhejiang, China
Jinhua Municipal Central Hospital

Jinhua, Zhejiang, China
Linfen Central Hospital

Linfen, Shanxi, China
Liupanshui Shougang Shuigang Hospital

Liupanshui, Guizhou, China
Loudi Central Hospital

Loudi, Hunan, China
Mianyang Central Hospital

Mianyang, Sichuan, China
Ningbo Medical Center Lihuili Hospital

Ningbo, Zhejiang, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China
Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China
Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China
Shanghai Tongji Hospital

Shanghai, Shanghai Municipality, China
Shenzhen Third People's Hospital

Shenzhen, Guangdong, China
Xiangya Hospital, Central South University

Changsha, Hunan, China
Xuzhou Central Hospital

Xuzhou, Jiangsu, China
Zhongshan Traditional Chinese Medicine Hospital

Zhongshan, Guangdong, China
Zhuzhou Central Hospital

Zhuzhou, Hunan, China
Zibo Central Hospital

Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.